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Background: Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a
variety of other symptoms in cattle. The economic losses due to mycoplasma pneumonia could be reduced by
antibiotic treatment. The aim of the present study was to determine the in vitro susceptibility of M. bovis strains
isolated from cattle in Hungary to eleven antibiotics.
Results: Minimal inhibitory concentration (MIC) values of 35M. bovis strains collected from different parts of
Hungary between 2010 and 2013 were determined by the microbroth dilution method. Strains with high MIC
values were found in the case of all applied antibiotics. The most effective antibiotics tested in vitro were
fluoroquinolones (MIC90 danofloxacin 0.312 μg/ml, enrofloxacin 0.312 μg/ml, marbofloxacin 0.625 μg/ml). Our
results confirm the observations of increasing MIC values to antibiotics commonly used in the therapy of
mycoplasma infections, primarily to tetracyclines; tetracycline (MIC90 16 μg/ml) and oxytetracycline (MIC90 ≥ 64 μg/ml)
and macrolides; tylosin (MIC90 ≥ 128 μg/ml) and tilmicosin (MIC90 ≥ 128 μg/ml). The growth of many M. bovis strains
was not inhibited by gentamicin (MIC90 8 μg/ml), spectinomycin (MIC90 ≥ 256 μg/ml), florfenicol (MIC90 8 μg/ml) or
lincomycin (MIC90 ≥ 64 μg/ml).
Conclusions: Our results emphasize the necessity of periodic testing for antibiotic susceptibility in this geographic
region. Based on our in vitro examinations, fluoroquinolones could be the most effective drugs for the therapy of
M. bovis infections in Hungary. However, current antimicrobial use policies have to be taken into account to avoid
further antibiotic resistance development and to reserve fluoroquinolones for the treatment of severe infections which
have responded poorly to other classes of antimicrobials.
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Mycoplasma bovis is a widely distributed pathogen, first
isolated in the USA in 1961 from a case of severe mastitis
in cattle [1]. It is associated with various diseases in cattle
including calf pneumonia, mastitis, arthritis, otitis media
and genital disorders [2]. M. bovis is considered respon-
sible for a quarter to a third of economic losses in the
cattle industry caused by respiratory diseases [3].* Correspondence: m.gyuranecz@gmail.com
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unless otherwise stated.In Hungary, the average seropositivity rate of individual
animals was found to be 11.3%, in certain herds it even
exceeded 50.0%. Tested by enzyme-linked immunosorbent
assay the overall rate of seropositive herds was 64.7% [4].
With the exception of seroprevalence on individual level,
these values are relatively high in a European context [3,5].
Since no effective vaccine is available against M. bovis,
adequate housing and appropriate antibiotic treatment
are promoted in the control of the diseases caused by
this agent. Antibiotic therapy of mastitis has often failed,
but antimicrobial treatment of pneumonia has shown
some success and it may help reduce economic losses
[3,6]. Mycoplasmas are intrinsically resistant to β-lactamLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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not possess a cell wall and do not synthesize folic acid.
Mycoplasmas are generally susceptible to antibiotics that
affect protein (tetracyclines, macrolides, lincosamides,
phenicols) or nucleic acid synthesis (fluoroquinolones)
[2]. The decreased effectiveness of certain antimicrobial
agents (spectinomycin, oxytetracycline and tilmicosin)
traditionally used in the therapy of mycoplasma infec-
tions was reported in Europe [7].
The aim of this study was to determine the susceptibility
of 35 Hungarian M. bovis isolates to eleven antibiotics
using the microbroth dilution method.
Methods
Thirty-five M. bovis strains originating from dairy herds
located in different parts of Hungary were tested in this
study (Table 1, Figure 1). The samples were collected
during routine diagnostic examinations or necropsies be-
tween 2010 and 2013. Ethical approval was not required
for the study as all samples were collected during routine
diagnostic examinations or necropsies. Nasal swabs, lung
samples and a single lymph node were homogenized in
2 ml of Mycoplasma broth medium (pH 7.8) (Thermo
Fisher Scientific Inc./Oxoid Inc./, Waltham, MA) supple-
mented with 0.5% (w/v) sodium pyruvate, 0.5% (w/v)
glucose and 0.005% (w/v) phenol red and cultured at 37°C
in a 5% CO2 atmosphere. Following colour change (red
to yellow shift) the cultures were inoculated onto solid
Mycoplasma media (Thermo Fisher Scientific Inc. /Oxoid
Inc./) and were incubated at 37°C and 5% CO2 for 3 days,
until visible colonies appeared. Mixed cultures were filter
cloned only once to exclude contaminant Mycoplasma
species and to minimize in vitro mutations of the isolates.
DNA extraction was performed using the QIAamp DNA
Mini Kit (Qiagen Inc., Hilden, Germany) according to the
manufacturers’ instructions for Gram-negative bacteria.
All isolates were identified by polymerase chain reaction
(PCR) targeting the uvrC gene of M. bovis [8]. The purity
of the cultures (e.g. to exclude M. arginini or other Myco-
plasma spp. contamination) was confirmed by a universal
Mycoplasma PCR system targeting the 16S/23S rRNA
intergenic spacer region in Mollicutes [9] followed by
sequencing on an ABI Prism 3100 automated DNA se-
quencer (Applied Biosystems, Foster City, CA), sequence
analysis and BLAST search. The same once filter cloned
passage of each M. bovis strain was submitted for a 4
gene based multi-locus sequence typing (MLST) and the
sequencing data confirmed the purity of the isolates at
strain level (i.e. not more than one M. bovis strain in the
culture) [10]. Mixed primary cultures which failed to be
purified by a single filter cloning were excluded from
the study (data not shown). Aliquots of the third passage
of purified cultures were stored frozen at −70°C until
required. The number of colour changing units (CCU)was calculated by microplate dilution method, from the
lowest dilution showing colour change after one week of
incubation [11,12].
The following antimicrobial agents were examined dur-
ing the microbroth dilution tests: three fluoroquinolones:
danofloxacin (batch SZBA019XV), enrofloxacin (batch
SZBA336XV) and marbofloxacin (batch SZBC248XV);
two aminoglycosides: gentamicin (batch 051K17475V)
and spectinomycin (batch SZBB166XV); two tetracyclines:
oxytetracycline (batch SZBC320XV) and tetracycline
(batch SZBA140XV); two macrolides: tilmicosin (batch
SZBC345XV) and tylosin (batch SZBB160XV); one phenicol:
florfenicol (batch SZBC223XV) and one lincosamide: linco-
mycin (batch SZBC340XV); all products originated from
VETRANAL, Sigma-Aldrich, Germany. They were diluted
and stored according to the recommendations of Hannan
[11]. Stock solutions of 1 mg/ml enrofloxacin, danofloxacin
and marbofloxacin were prepared in 0.1 M NaOH; stock so-
lution of 1 mg/ml florfenicol was prepared in 96% ethanol
and in sterile distilled water; and the rest of the stock solu-
tions of 1 mg/ml were prepared in sterile distilled water. All
aliquots were stored at −70°C until needed, and dilutions
were freshly prepared for each microtest. Twofold dilutions
were prepared in the range 0.039-10 μg/ml for fluoroquino-
lones, 0.125-32 μg/ml for florfenicol, 0.25-64 μg/ml for
gentamicin, tetracyclines and lincomycin, 0.5-128 μg/ml for
macrolides and 1–256 μg/ml for spectinomycin.
The microbroth dilution test was performed as recom-
mended by Hannan [11] using 104-105 CCU/ml of each
strain. In brief, the 96-wells microtiter plates were designed
to contain growth control (broth medium without anti-
biotic), sterility control (broth medium without antibiotic
and Mycoplasma inoculum) and pH control (broth medium
adjusted to pH 6.8) wells. Mycoplasma broth medium
(pH 7.8) (Thermo Fisher Scientific Inc./Oxoid Inc./) supple-
mented with 0.5% (w/v) sodium pyruvate, 0.5% (w/v) glu-
cose and 0.005% (w/v) phenol red was used as a culture
medium. The duplicates of three clinical isolates and the du-
plicate of the type strain (M. bovis PG45, NCTC 10131)
were tested on each 96-well microtiter plates.
The MIC (minimal inhibitory concentration) value
of each isolate was defined as the lowest concentration
of the antibiotic that completely inhibits the growth in
the broth (no pH and colour change) after a one week
incubation period [12]. MIC50 and MIC90 values were
defined as the lowest concentrations that inhibit 50%
and 90% of bacterial isolates. The type strain (M. bovis
PG45, NCTC 10131) was used for the quality control of
MIC determination (Table 1).
Results
Our MIC values of M. bovis type strain PG45 were iden-
tical with values previously obtained for danofloxacin,
enrofloxacin, marbofloxacin, spectinomycin, tilmicosin








Fluoroquinolones Aminoglycosides Tetracyclines Macrolides Phenicol Lincosamide
Danofloxacin Enrofloxacin Marbofloxacin Gentamicin Spectinomycin Oxytetracycline Tetracycline Tilmicosin Tylosn Florfenicol Lincomycin
PG45 Connecticut 1961 Lung 0.156 0.156 0.625 4 4 2 0.25 0.5 0.5 4 1
MYC2 Püspökhatvan 2011 Lung 0.156 0.156 0.625 2 2 16 4 128 16 4 1
MYC22 Sümeg 2012 Lung 0.156 0.312 0.625 4 256 64 16 128 128 8 64
MYC30 Bugyi 2012 Lung 0.156 0.156 0.625 4 256 32 8 128 128 4 64
MYC42 Nemti 2012 Lung 0.156 0.156 0.625 8 4 64 8 128 32 8 1
MYC43 Zsana 2012 Lung 0.156 0.156 0.312 4 256 64 16 128 128 8 64
MYC44 Győrszentiván 2012 Lung 10 10 10 2 256 64 8 128 128 8 64
MYC45 Budapest 2012 Lung 10 10 10 2 256 64 8 128 128 4 64
MYC46 Budapest 2012 Lung 10 10 10 4 256 64 8 128 128 8 64
MYC47 Dabas 2012 Lung 0.156 0.156 0.625 8 256 64 8 128 128 8 64
MYC48 Ősi 2012 Nasal
swab
0.156 0.156 0.625 8 256 64 16 128 128 4 64
MYC49 Ősi 2012 Nasal
swab
0.156 0.156 0.625 8 256 64 16 128 128 4 64
MYC50 Ősi 2012 Lung 0.156 0.156 0.625 4 256 64 8 128 128 4 64
MYC51 Ősi 2012 Nasal
swab
0.156 0.08 0.312 4 256 64 8 128 128 4 64
MYC52 Solt 2012 Lung 0.156 0.156 0.312 8 4 2 0.25 0.5 0.5 4 0.5
MYC53 Solt 2012 Lung 0.156 0.156 0.625 16 4 2 0.25 0.5 0.5 4 1
MYC65 Csengersima 2012 Nasal
swab
0.156 0.156 0.625 2 2 64 16 128 8 4 0.5
MYC66 Csengersima 2012 Nasal
swab
0.156 0.156 0.625 8 4 64 8 128 16 8 1
MYC67 Csengersima 2012 Lung 0.08 0.08 0.312 4 4 16 4 128 16 8 2
MYC68 Csengersima 2012 Lung 0.156 0.156 0.625 4 4 32 4 128 16 4 0.5
MYC69 Komárom 2013 Nasal
swab
0.156 0.156 0.625 2 4 32 8 128 32 8 1
MYC70 Komárom 2013 Nasal
swab
0.156 0.156 0.625 4 2 32 4 128 32 4 1
MYC71 Komárom 2013 Nasal
swab
0.156 0.156 0.625 4 2 32 4 128 32 4 1
MYC72 Komárom 2013 Nasal
swab
0.156 0.156 0.625 4 4 32 4 128 32 4 1
MYC73 Komárom 2013 Nasal
swab


















Table 1 Background information and MIC data of the 35 Hungarian M. bovis isolates included in this study (Continued)
MYC74 Komárom 2013 Nasal
swab
0.156 0.156 0.625 4 4 32 8 128 16 4 1
MYC75 Komárom 2013 Nasal
swab
0.156 0.08 0.312 2 2 32 4 128 32 4 1
MYC76 Komárom 2013 Nasal
swab
0.156 0.156 0.625 4 4 64 8 128 16 8 2
MYC77 Kertészsziget 2010 Lung 0.312 0.156 0.625 2 256 64 8 128 128 4 64
MYC78 Hosszúpályi 2011 Lung 0.156 0.156 0.625 4 256 64 8 128 128 4 64
MYC79 Hosszúpályi 2011 Lung 0.156 0.156 0.625 8 256 64 16 128 128 8 64
MYC80 Ebes 2011 Lymph
node
0.156 0.156 0.625 4 256 32 4 128 128 4 64
MYC81 Felsőnyárád 2013 Lung 0.156 0.156 0.625 8 256 64 8 128 128 4 64
MYC82 Felsőnyárád 2013 Nasal
swab
0.156 0.156 0.625 4 256 64 8 128 128 8 64
MYC83 Alsótold 2013 Lung 0.312 0.156 0.625 4 256 64 8 128 128 8 64
MYC84 Felsőnyárád 2013 Nasal
swab




































Figure 1 Map of Hungary showing the geographical origins of the 35M. bovis isolates tested.
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[12,13]. The MIC value of PG45 (2 μg/ml) for oxytetracyc-
line was within the range of previously published studies
applying microbroth dilution test (0.1/0.125/0.16/4 μg/ml)
[6,11-13]. The MIC value (1 μg/ml) of PG45 for lincomy-
cin was higher than in a previous study (0.25 μg/ml) [13].
For gentamicin, tetracycline, and florfenicol data deter-
mined by microbroth dilution test were not available. Our
results for type strain PG45 were consistent throughout
the study.
The MIC values of the eleven antimicrobial agents ob-
tained from the examinations of the Hungarian M. bovis
isolates are shown in Figure 2 and listed in Tables 1 and
2. Strains with elevated MIC values were found in the
case of all applied antibiotics. Fluoroquinolones were
found to be the most active compounds in vitro. The anti-
biotic susceptibility profiles of the Hungarian strains were
consistent within the tested group of fluoroquinolones
(Figure 2A-C). Three isolates (MYC44, MYC45 and
MYC46) had high MIC values (≥10 μg/ml) to danofloxa-
cin, enrofloxacin and marbofloxacin, while the rest of the
strains were inhibited by these antimicrobial agents with
MICs ≤0.312 or 0.625 μg/ml. The MICs for gentamicin
clustered steadily around the MIC50 value (4 μg/ml)
(Figure 2D). MIC values of spectinomycin divided the
strains into two distinct populations, with 48% of isolatesyielding MICs of ≤4 μg/ml and the rest clustering with
MICs ≥256 μg/ml (Figure 2E). Two M. bovis isolates
(MYC52 and MYC53) originating from the same herd
were inhibited by both tetracyclines and macrolides with
low MIC values (Figure 2F-I). Among the macrolides, the
MICs of tilmicosin showed bimodal distribution, as two
strains yielded MICs ≤0.5 μg/ml, while the rest yielded
MICs ≥128 μg/ml. The narrow range of MIC values
(4–8 μg/ml) of florfenicol is demonstrated on Figure 2J.
MICs for lincomycin also clustered the strains into a
group with MICs ≤2 μg/ml and with MICs ≥64 μg/ml
(Figure 2K).
Isolates originating from the same herd showed similar
antibiotic susceptibility profiles (Table 1).
Discussion
Gerchman et al. [13] studied 11M. bovis strains isolated
from cattle imported from Hungary to Israel between
2005 and 2007. The most active compounds found during
in vitro examinations were fluoroquinolones (danofloxacin,
enrofloxacin and marbofloxacin), which is in accordance
with our results, except that the MIC values described
before were higher than the ones detected in this study
(MIC90 1.25 μg/ml, 1.25 μg/ml, 5 μg/ml versus 0.312 μg/ml,
0.312 μg/ml, 0.625 μg/ml). Decreased spectinomycin
susceptibility was detected in the strains from the imported
Figure 2 MIC distribution of the Hungarian isolates for each antibiotic tested in this study. Arrows indicate the MIC50 and MIC90 values.
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which is consistent with our results (MIC90 ≥ 256 μg/ml). In
contrast to the results obtained by Gerchman et al. [13]
(4 μg/ml, 8 μg/ml, 1 μg/ml) the MIC90 values of oxytetracyc-
line (≥64 μg/ml), tilmicosin (≥128 μg/ml) and tylosin
(≥128 μg/ml) yielded in the present study indicate limited
susceptibility to these antibiotics. The comparison of
the results of the previous publication and the present
study emphasize the importance of the systematic mon-
itoring of antibiotic susceptibility of M. bovis strains in
the region [13,14].
Fluoroquinolones inhibited the growth of the majority
of the Hungarian M. bovis strains at low MIC values (with
only 3 exceptions), confirming previous observations thatTable 2 Summary of range, mode, MIC50 and MIC90 values of
Range
Fluoroquinolones Danofloxacin 0.078 to ≥
Enrofloxacin 0.078 to ≥
Marbofloxacin 0.312 to ≥
Aminoglycosides Gentamicin 2 to 16
Spectinomycin 2 to ≥256
Tetracyclines Oxytetracycline 2 to ≥64
Tetracycline ≥0.25 to 1
Macrolides Tylosin ≥0.5 to ≥
Tilmicosin ≥0.5 to ≥
Phenicol Florfenicol 4 to 8
Lincosamide Lincomycin 0.5 to ≥64
All values are expressed as μg/ml.this group of antimicrobial agents is effective against
M. bovis [6,7,13-18]. MIC values of marbofloxacin were
remarkably higher than that of danofloxacin and enroflox-
acin. The observed difference, first noted by Gerchman
et al. [13] is probably due to the increased use of marbo-
floxacin during the past years [13]. Extremely high MIC
values for fluoroquinolones (≥10 μg/ml) were found in
strains MYC44-46. The similarity in the resistance profile
of these three strains is consistent with the results of a pre-
vious genetic study in the country, where these strains
clustered into a separate subclade by MLST [10].
Most Hungarian M. bovis strains included in the present
examination showed moderate susceptibility to gentami-
cin, with similar or lower MIC values (MIC90 8 μg/ml)the 35M. bovis strains isolated from cattle in Hungary
Mode MIC50 MIC90
10 0.156 0.156 0.312
10 0.156 0.156 0.312




6 8 8 16
128 ≥128 ≥128 ≥128
128 ≥128 ≥128 ≥128
4 4 8
≥64 ≥64 ≥64
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32 μg/ml) [13,19]. Spectinomycin, another member of the
aminoglycosides, was used traditionally as an active com-
pound against M. bovis and it is still considered effective
in Japan [6,12,14]. However, high MIC values of spectino-
mycin (≥256 μg/ml) were observed in more than half of
the studied Hungarian isolates, which is in agreement with
recent reports from other countries [7,13,15-17,19], con-
firming a globally emerging resistance to spectinomycin.
Heterogenic profiles of M. bovis susceptibility to tetracy-
clines are reported from all over the world [6,7,13,14,16,19].
Only two Hungarian isolates showed low MIC value to
oxytetracycline and tetracycline, demonstrating the high
level of resistance to tetracyclines among the strains. In
accordance with our results, increasing resistance to oxy-
tetracycline was reported previously in Britain, Belgium,
Japan and France [7,14,16,19].
All but two of the Hungarian M. bovis strains showed
high level of resistance to macrolides, with MIC90 values
(≥128 μg/ml) consistent with previously published data,
suggesting that macrolides are losing their efficacy on
mycoplasmas [6,7,13,14,16]. For example an earlier clin-
ical study demonstrated the effective use of tilmicosin
[20] but another study [21] twelve years later already
demonstrated the ineffectiveness of tilmicosin against
M. bovis in vivo which also emphasizes the spread of
antibiotic resistance due to the escalating use of antibi-
otics in veterinary practice. In the present study MICs
of tilmicosin grouped around two distinct values,
while the distribution of MICs of tylosin was gradually
dispersed (Figure 2H-I). MIC values of tylosin were
lower (8-128 ≤ μg/ml) or similar to MICs of tilmicosin
(≥128 μg/ml). Similar observations were reported in the
case of M. bovis strains by Gerchman et al. [13] and
in the case of M. gallisepticum isolates by Jordan and
Horrocks [22]. The slower development of tylosin resist-
ance is supposed to be the cause of the difference between
the MIC values of these antibiotics [23], and our results
provide further evidence for this phenomenon.
Outstandingly low MIC values of all tetracyclines and
macrolides were observed in two Hungarian isolates ori-
ginating from the same herd (MYC52-53) and in the case
of the reference PG45 strain. These three strains were
closely related and they also formed a separate genetic
clade in the MLST analysis performed previously [10].
The Hungarian isolates showed high MIC values to flor-
fenicol. The MIC90 values (8 μg/ml) were similar to values
obtained earlier in the United Kingdom (16 μg/ml), USA
(4 μg/ml) and France (16 μg/ml) [6,7,16].
MIC90 values of lincomycin (≥64 μg/ml) were higher
than the ones (1 μg/ml, 8 μg/ml, 64 μg/ml) described
elsewhere [12,14,19]; and more than half of the strains
isolated from cattle in Hungary demonstrated high MIC
values to this member of lincosamides.The results of in vitro antibiotic susceptibility tests can
only predict the expected in vivo efficacy of the antibiotics,
thus they only indicate the potential usefulness of a certain
antimicrobial agent in the therapy. Standard breakpoints
(susceptible, intermedier, resistant categories) have not yet
been defined for the interpretation of M. bovis susceptibil-
ity to antibiotics [24], but several authors derived break-
points for mycoplasmas from breakpoints of other bovine
pathogens, and in some cases values were adopted from
other host species [6,13-17]. Taking into account all these
criteria, fluoroquinolones seem to be the most active com-
pounds in vivo against the M. bovis strains existing in
Hungary. Although the in vitro antibiotic susceptibility
tests are promising, the use of fluoroquinolones against
M. bovis could be controversial in vivo. In the United
Kingdom Nicholas and Ayling [3] reported on a study
where the monthly fluoroquinolone treatment repeated
over three months did not prevent the development of
respiratory disease caused by M. bovis.Conclusions
The present study determined the antibiotic susceptibility
profiles of 35M. bovis strains isolated from cattle in
Hungary and it highlighted the importance of regular test-
ing of antibiotic susceptibility in the region. Our results
confirmed the increasing resistance to antibiotics com-
monly used for the treatment of mycoplasma infections,
primarily to tetracyclines and macrolides. Based on the
presented in vitro examinations, fluoroquinolones could be
the most effective in the therapy of M. bovis infections in
Hungary. However, the identification of three fluoroquino-
lon resistant isolates lends support for the EU recommenda-
tion that prudent antimicrobial use policies have to be
strictly observed when members of this antibiotic group are
applied [25]. In order to avoid the development of resistance
fluoroquinolones should only be used based on the results
of susceptibility testing and in cases of severe infections
when treatment failed with other classes of antimicrobials.
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